| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- INCB-057643
-
- $35.00
-
2026-07-14
- CAS:1820889-23-3
- Purity: 99.58%
- Supply Ability: 10g
|
| | incb057643 Basic information |
| Product Name: | incb057643 | | Synonyms: | incb057643;CS-2906;INCB;2H-1,4-Benzoxazin-3(4H)-one, 8-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-2,2,4-trimethyl-6-(methylsulfonyl)-;INCB057643,Apoptosis,Epigenetic Reader Domain,inhibit,INCB 057643,INCB-057643,Inhibitor;2,2,4-Trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one;INCB-057643, 10 mM in DMSO | | CAS: | 1820889-23-3 | | MF: | C20H21N3O5S | | MW: | 415.46 | | EINECS: | | | Product Categories: | | | Mol File: | 1820889-23-3.mol |  |
| | incb057643 Chemical Properties |
| Boiling point | 787.7±60.0 °C(Predicted) | | density | 1.370±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:6): 0.14 mg/ml | | form | A crystalline solid | | pka | 14.74±0.40(Predicted) | | color | White to off-white |
| | incb057643 Usage And Synthesis |
| Uses | INCB-057643, is a novel, orally bioavailable BET inhibitor. | | in vivo | Production of several cytokines, including IL-6, IL-10 and MIP-1α, is repressed by INCB-057643 in human and mouse whole blood stimulated ex vivo with LPS. Oral administration of INCB-057643 results in significant anti-tumor efficacy in xenograft models of AML, myeloma, and DLBCL. Additionally, combining INCB-057643 with standard of care agents used for the treatment of DLBCL including rituximab and bendamustine results in enhanced anti-tumor efficacy relative to that achieved with single agent therapies at doses that are well tolerated[1]. |
| | incb057643 Preparation Products And Raw materials |
|